Advertisement
Galera Therapeutics Inc. (GRTX)
Galera Therapeutics Statistics
Share Statistics
Galera Therapeutics has 75.46M shares outstanding. The number of shares has increased by 38.74% in one year.
| Shares Outstanding | 75.46M |
| Shares Change (YoY) | 38.74% |
| Shares Change (QoQ) | 38.74% |
| Owned by Institutions (%) | 0.1% |
| Shares Floating | 31.8M |
| Failed to Deliver (FTD) Shares | 72.28K |
| FTD / Avg. Volume | 68.5% |
Short Selling Information
The latest short interest is 2.12M, so undefined% of the outstanding shares have been sold short.
| Short Interest | 2.12M |
| Short % of Shares Out | n/a |
| Short % of Float | 5.32% |
| Short Ratio (days to cover) | 1.16 |
Valuation Ratios
The PE ratio is -0.13 and the forward PE ratio is -0.04. Galera Therapeutics's PEG ratio is 0.
| PE Ratio | -0.13 |
| Forward PE | -0.04 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -0.02 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Galera Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6, with a Debt / Equity ratio of 0.
| Current Ratio | 6 |
| Quick Ratio | 6 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | - |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.71M |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -203K |
| Effective Tax Rate | 1.06% |
Stock Price Statistics
The stock price has increased by -81.48% in the last 52 weeks. The beta is 2.06, so Galera Therapeutics's price volatility has been higher than the market average.
| Beta | 2.06 |
| 52-Week Price Change | -81.48% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.06 |
| Relative Strength Index (RSI) | 29.87 |
| Average Volume (20 Days) | 105.5K |
Income Statement
| Revenue | n/a |
| Gross Profit | -3.84M |
| Operating Income | -20.16M |
| Net Income | -18.96M |
| EBITDA | -20.16M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.35 |
Balance Sheet
The company has 8.29M in cash and 0 in debt, giving a net cash position of 8.29M.
| Cash & Cash Equivalents | 8.29M |
| Total Debt | 0 |
| Net Cash | 8.29M |
| Retained Earnings | -456.36M |
| Total Assets | 8.9M |
| Working Capital | 7.99M |
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0.
| Operating Cash Flow | 0 |
| Capital Expenditures | 0 |
| Free Cash Flow | 0 |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for GRTX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -77.23 |
| Piotroski F-Score | 3 |